SNC 115
Alternative Names: SNC-115Latest Information Update: 13 May 2024
At a glance
- Originator Shanghai Simnova Biotechnology
- Class Antineoplastics; CAR-NK cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Neuroendocrine carcinoma; Small cell lung cancer
Most Recent Events
- 30 Apr 2024 Phase-I clinical trials in Neuroendocrine carcinoma (Second-line therapy or greater) in China (Parenteral) (NCT06384482)
- 30 Apr 2024 Phase-I clinical trials in Small cell lung cancer (Second-line therapy or greater) in China (Parenteral) (NCT06384482)